美國全球 Rozanolixizumab（Rystiggo）市場：市場規模、佔有率、趨勢分析（按適應症和分銷管道）、細分市場預測（2025-2033）

美國Rozanolixizumab（Rystiggo）市場概況

美國Rozanolixizumab (Rystiggo) 市場規模預計在2024年達到1.9913億美元，預計2025年至2033年的複合年成長率為7.30%。美國Rozanolixizumab (Rystiggo) 市場專注於治療攜帶抗乙醯膽鹼受體 (AChR) 或抗麝香 (MuSK) 抗體的成人重症全身性重症肌無力 (gMG)。在美國醫療基礎設施和報銷政策的支持下，對生物目標的需求正在推動市場成長。

美國FDA於2023年6月核准rozanolixizumab (Rystiggo)用於治療鉅細胞性肌無力(gMG)，將推動美國市場的成長。鉅細胞性肌無力(gMG)的診斷數量不斷成長（估計每10萬美國成年人中有3.2人確診），以及針對自體免疫疾病的生物製藥需求的不斷成長，共同推動著市場的成長。 UCB製藥專注於皮下給藥，這提高了患者的便利性，並支持了市場的擴張。預計到2033年，該市場規模將達到7.3298億美元，複合年成長率高達7.30%。

Rozanolixizumab (Rystiggo) 因其作用機製而脫穎而出，即透過抑制 FcRn 來降低 IgG 水平，與傳統免疫抑制劑相比，它提供了一種新穎的治療方法。核准用於抗乙醯膽鹼受體 (AChR) 和抗麝香 (MuSK) 抗體陽性患者，擴大了其市場覆蓋範圍。其競爭優勢包括副作用更少、給藥方式靈活，使其在與依加替莫德 (efgartigimod) 等替代藥物的競爭中佔據優勢。優時比 (UCB) 的行銷工作重點突出了這些優勢，目標客戶是神經科和專科診所。

新興創新包括針對慢性脫髓鞘多發性神經炎(CIDP) 等其他適應症的試驗，這可能會擴大 gMG 以外的市場。美國憑藉其研究基礎設施處於領先地位，2024 年的臨床試驗數據表明，到 2027 年，該藥物將得到更廣泛的應用。透過專科藥局和電商平台加強分銷，順應病患可及性趨勢，將進一步支持成長。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章美國Rozanolixizumab（Rystiggo）市場：促進因素、趨勢與範圍

• 市場聯動展望
• 市場動態
  • 市場促進因素分析
  • 市場限制分析
• 商業環境分析
  • 產業分析：波特五力分析
  • PESTEL分析
  • 管道分析
  • 專利到期分析
  • 定價分析

第4章美國Rozanolixizumab（Rystiggo）市場：按適應症進行的商業分析

• 各適應症市場佔有率（2024 年及 2033 年）
• 細分儀表板：依指示
• 市場規模預測及趨勢分析（2021-2033）
• 全身性重症肌無力（gMG）
• 新的管道應用

第5章美國Rozanolixizumab（Rystiggo）市場：按通路進行的業務分析

• 按分銷管道分類的市場佔有率（2024 年和 2033 年）
• 細分儀表板：按分銷管道
• 按分銷管道分類的市場規模預測和趨勢分析（2021-2033 年）
• 醫院和專科藥房
• 零售與電子商務

第6章 競爭態勢

• 參與企業概況
• 企業市場分析
• 公司分類
• 戰略地圖
• 公司簡介/上市公司
  • UCB

U.S. Rozanolixizumab (Rystiggo) Market Summary

The U.S. Rozanolixizumab (Rystiggo) market size was estimated at USD 199.13 million in 2024 and is expected to grow at a CAGR of 7.30% from 2025 to 2033. The U.S. Rozanolixizumab (Rystiggo) market focuses on treating generalized myasthenia gravis (gMG) in adults with anti-AChR or anti-MuSK antibodies. Growth is driven by demand for targeted biologics, supported by U.S. healthcare infrastructure and reimbursement policies.

The U.S. Rozanolixizumab (Rystiggo) market benefits from the drug's FDA approval in June 2023 for gMG treatment. Growth is propelled by rising gMG diagnoses, estimated at 3.2 per 100,000 U.S. adults for the MG cases, and increasing demand for biologics targeting autoimmune disorders. UCB Pharma's focus on subcutaneous administration enhances patient convenience, supporting market expansion. Projections to USD 732.98 million by 3033 reflect a steady CAGR of 7.30%, driven by ongoing clinical advancements and healthcare investments.

Rozanolixizumab (Rystiggo) stands out due to its mechanism of action, reducing IgG levels via FcRn inhibition, offering a novel approach compared to traditional immunosuppressants. Its approval for both anti-AChR and anti-MuSK antibody-positive patients broadens its market scope. Competitive advantages include fewer side effects and flexible dosing, positioning it favorably against alternatives such as efgartigimod. UCB's marketing efforts emphasize these benefits, targeting neurologists and specialty clinics.

Emerging innovations include trials for additional indications, such as chronic inflammatory demyelinating polyneuropathy (CIDP), which could expand the market beyond gMG. The U.S. leads due to its research infrastructure, with clinical trial data from 2024 suggesting broader applications by 2027. Distribution enhancements via specialty pharmacies and e-commerce platforms further support growth, aligning with patient access trends.

U.S. Rozanolixizumab (Rystiggo) Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Rozanolixizumab (Rystiggo) market report based on indication and distribution channel:

• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Generalized Myasthenia Gravis (gMG)
• Emerging Pipeline Applications
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital & Specialty Pharmacies
• Retail & E Commerce

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Indication
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Rozanolixizumab (Rystiggo) Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Rozanolixizumab (Rystiggo) Market: Indication Business Analysis

• 4.1. Indication Market Share, 2024 & 2033
• 4.2. Indication Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
• 4.4. Generalized Myasthenia Gravis (gMG)
  • 4.4.1. Generalized Myasthenia Gravis (gMG) Market, 2021 - 2033 (USD Million)
• 4.5. Emerging Pipeline Applications
  • 4.5.1. Emerging Pipeline Applications Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Rozanolixizumab (Rystiggo) Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital & Specialty Pharmacies
  • 5.4.1. Hospital & Specialty Pharmacies Market, 2021 - 2033 (USD Million)
• 5.5. Retail & E-Commerce
  • 5.5.1. Retail & E-Commerce Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. UCB
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Rozanolixizumab (Rystiggo) market, by indication, 2021 - 2033 (USD Million)
• Table 4 U.S. Rozanolixizumab (Rystiggo) market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Rozanolixizumab (Rystiggo) market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Million)
• Fig. 10 Competitive landscape
• Fig. 11 U.S. Rozanolixizumab (Rystiggo) Market dynamics
• Fig. 12 U.S. Rozanolixizumab (Rystiggo) Market: Porter's five forces analysis
• Fig. 13 U.S. Rozanolixizumab (Rystiggo) Market: PESTLE analysis
• Fig. 14 Indication market, 2021 - 2033 (USD Million)
• Fig. 15 Generalized Myasthenia Gravis (gMG) market, 2021 - 2033 (USD Million)
• Fig. 16 Emerging Pipeline Applications market, 2021 - 2033 (USD Million)
• Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
• Fig. 18 Hospital & Specialty Pharmacies market, 2021 - 2033 (USD Million)
• Fig. 19 Retail & E-Commerce market, 2021 - 2033 (USD Million)
• Fig. 20 U.S. Rozanolixizumab (Rystiggo) Market revenue, by region
• Fig. 21 Regional marketplace: Key takeaways
• Fig. 22 U.S. country dynamics
• Fig. 23 U.S. Rozanolixizumab (Rystiggo) market, 2021 - 2033 (USD Million)
• Fig. 24 Company categorization
• Fig. 25 Company market position analysis
• Fig. 26 Strategic framework